Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II personalized neoadjuvant treatment for locally advanced rectal cancer
jRCTs021210076Phase 2Recruiting
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal cancer. Primary endpoint: 3-year disease-free survival rate. Started May 2022; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs021210076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210076.